Jahan Marcu

Jahan Marcu, Ph.D is one of the top researchers and industry experts in the field, contributing to many innovative discoveries, applications, and standards for medical cannabis and its laboratory analysis, cultivation, manufacturing, and dispensing. He is a court qualified expert witness for cannabis and synthetic drugs, and is cited in case law. Dr. Marcu has also created training for the industry and internationally accepted methods for cannabis analysis, and has founded institutions and organizations for research, education, and training programs. He became well-known for demonstrating synergistic interactions for cannabinoids such as THC and CBD in cancer, which has led to the development and marketing of products with those ratios and launched numerous applications and research projects. He helped create the first product standards for cannabis and hemp products, as a chairman of the American Herbal Products Association (AHPA) cannabis committee. Those standards are now being reviewed by ASTM, where he was accepted as a chairman of D37.07 for the committee on cannabis standards for training, certification, and accreditation. Dr. Marcu’s additional work includes helping to solve the structure of cannabinoid receptors , characterized a class of drugs for cannabinoid receptors called allosteric modulators, and co-authored the first product safety study on Cannabidiol (CBD) products . He is also an author of the American Herbal Pharmacopoeia Cannabis monograph, which help set standards for cannabis and hemp products for human consumption. His test methods have received national media attention and has been interviewed by Science and Nature for his contributions to basic research and applied innovations. His studies have been covered by numerous cannabis industry journals, and national media outlets. His work has received praise and used by both regulators, policy makers, and scientists, as addressing an urgent national need. His research and standards documents are often cited in regulations and used to develop medical cannabis programs.